From the Journals
Conference News
Risk Model Stratifies Heart Failure Outcomes
Biomarker score estimates risk and absolute benefit of finerenone across patient groups
A recent analysis from the FINEARTS-HF trial demonstrated that a biomarker-driven risk model effectively stratifies patient outcomes among those with heart failure and preserved or mildly reduced ejection fraction. This secondary analysis included 6,001 patients aged 40 or older, examining the efficacy of finerenone compared to placebo over a median follow-up of 32 months. Findings indicated that finerenone consistently reduced composite heart failure hospitalization or cardiovascular death across various risk quintiles, underscoring its potential benefit in high-risk patients, while also noting increased incidences of certain side effects.
